Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Once in the body, tPA has can cause the desired thrombolytic activity (see figure), or be inactivated and removed. In the bloodstream tPA has a half-life of 4 to 6 minutes. tPA can be bound by a plasminogen activator inhibitor, resulting in inactivation of its activity. The protein is then removed from the bloodstream by the liver. One of the specific receptors responsible for this processes is a protein known as the LDL Receptor-Related Protein (LRP1), which clears tPA which is bound to the Plasminogen Activator Inhibitor 1 (PAI-1). However, when present in a high enough concentration to counteract the effects of plasminogen activator inhibitor, tPA can bind plasminogen, cleaving off the bound plasmin from it. Plasmin, another type of protease, can either be bound by a plasmin inhibitor, or work to degrade fibrin clots, which is the main therapeutic pathway.
=== Pharmacokinetics === Alexander Shulgin has noted that 6-HO-DET may have poor blood–brain barrier permeability due to its exposed hydroxyl group and consequent polarity analogously to bufotenin (5-HO-DMT).
A test tube, also known as a culture tube or sample tube, is a common piece of laboratory glassware consisting of a finger-like length or longer of glass or clear plastic tubing, open at the top and closed at the bottom. Test tubes are usually placed in special-purpose racks.
== Operations == CosMc's was intended to sell afternoon snacks and hot and cold drinks, and was seen as an attempt by McDonald's to enter the United States coffee market and the growing market for drive-thru beverages. CosMc's outlets had a smaller footprint than a regular McDonald's. It carried a range of products that were not available at regular McDonald's, such as 10 new beverages. It also sold foods available at McDonald's, such as the Egg McMuffin. The first CosMc's shop had four drive thrus.
Sources: en.wikipedia.org
An IOC official stated that endocrine profiles done at those games indicated that 80 percent of the track and field athletes tested showed evidence of long-term steroid use, although not all were banned.
== Diagnosis == Substance use disorders can be confused with other psychiatric disorders. There are diagnoses for substance-induced mood disorders and substance-induced anxiety disorders and thus such overlap can be complicated. For this reason, the DSM-IV advises that diagnoses of primary psychiatric disorders not be made in the absence of sobriety (of a duration sufficient to allow for any substance-induced post-acute-withdrawal symptoms to dissipate) up to 1 year.
== System software == Honeywell provided up to 500 software packages that could run on the H-316 processor. A FORTRAN IV compiler was available, as well as an assembler, real-time disk operating systems and system utilities and libraries.
Sources: en.wikipedia.org
Peukert argued that despite a turn towards Social Darwinism when confronted with the failure of the welfare state to solve all social problems in the 1920s, that it was the democratic Weimar constitution that had provided a thin legal wedge that prevented the full implications of this from being worked out. Peukert argued that in 1939 that the entire system that had been built up for scientifically identifying those of racial "non-value" served as the apparatus for genocide. Peukert wrote that all of the criteria for identifying Jews and Romany as peoples of racial "non-value" were based on the pseudo-scientific theories that had been promoted by generations of "race scientists" and that those serving in the "human sciences and social professions" worked to provide the theories for an "all-embracing racist restructuring of social policy, educational policy and health and welfare policy". The culmination of these efforts was the proposed 1944 "Law for the Treatment of Community Aliens" which called for sending to the concentration camps anyone who failed to live be up to be a proper 'volksgenossen as a gemeinschaftsfremde (community alien). Only the fact that Germany was fully engaged in World War II prevented Hitler from signing "Law for the Treatment of Community Aliens", which was put off until the Reich won the "final victory". Peukert wrote: "Nazi racism, the professed goal which had been to secure the immortality of the racially pure volkskörper in practice inevitably became converted into a crusade against life".
Singapore has a tropical rainforest climate (Köppen: Af) with no distinctive seasons, uniform temperature and pressure, high humidity, and abundant rainfall. Temperatures usually range from 23 to 32 °C (73 to 90 °F). While temperature does not vary greatly throughout the year, there is a wetter monsoon season from November to February. From July to October, there is often haze caused by bush fires in neighbouring Indonesia, usually from the island of Sumatra. Singapore follows the GMT+8 time zone, one hour ahead of the typical zone for its geographical location. This causes the sun to rise and set particularly late during February, where the sun rises at 7:15 am and sets around 7:20 pm. During July, the sun sets at around 7:15 pm. The earliest the sun rises and sets is in late October and early November when the sun rises at 6:46 am and sets at 6:50 pm. Singapore recognises that climate change and rising sea levels in the decades ahead will have major implications for its low-lying coastline. It estimates that the nation will need to spend $100 billion over the course of the next century to address the issue. In its 2020 budget, the government set aside an initial $5 billion towards a Coastline and Flood Protection Fund. Singapore is the first country in Southeast Asia to levy a carbon tax on its largest carbon-emitting corporations producing more than 25,000 tons of carbon dioxide per year, at $5 per ton.
==== Suicides and homicides ==== Tyson Mathews (1983–2013) died in Teralba, New South Wales, Australia, on 7 November 2013 just six days after his 30th birthday. The cause of death was determined to be suicide by hanging. At the time of his death, he was subject to a community treatment order (CTO) mandating depot antipsychotic injections of paliperidone palmitate (brand name Invega Sustenna). The inquest specifically investigated whether this medication was a contributing factor. His mother was concerned about the appropriateness of paliperidone palmitate. She observed that after the dose was increased, her son's psychotic symptoms settled, but he became "markedly more depressed." She questioned whether the drug contributed to his condition and death. Despite his depression (neuroleptic dysphoria) worsening, Ms. Mathews felt healthcare professionals did not fully acknowledge the deterioration. Andrew Jeffrey Rich (1989–2019) was a Wisconsin man placed under court-ordered assisted outpatient treatment (AOT) following a breakdown in May 2017. He was required to receive regular injections of Invega Sustenna under Wisconsin's Chapter 51 commitment law. Over approximately 18 months, recommitment orders were repeatedly extended on the basis that he denied having a mental illness and would likely stop medication if released, despite his psychiatrist acknowledging no observed psychotic symptoms during that period and Rich living and working independently in the community.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.